Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Olorinab (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 (CB2) agonist. With an EC50 of 6.2 nM for hCB2.
Description | Olorinab (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 (CB2) agonist. With an EC50 of 6.2 nM for hCB2. |
Targets&IC50 | hCB2:(EC50)6.2 nM |
In vitro | A comprehensive in vitro profile of Olorinab (APD 371) (6) shows that single digit nanomolar potency and full intrinsic efficacy are maintained in all species assessed. Olorinab (APD 371) is highly selective for CB2 over CB1 in both binding and functional assays. Olorinab (APD 371) induces efficient receptor internalization (~106% relative to the CB1/2 agonist CP55,940) in CHO cells expressing HA-tagged rat CB2 suggesting that, according to the hypothesis, Olorinab (APD 371) would be able to drive agonist-induced receptor recycling[1]. |
In vivo | Olorinab (APD 371) significantly increases paw withdrawal thresholds at doses ≥3 mg/kg PO (ED50=2.3 mg/kg). The analgesic effects of Olorinab (APD 371) are shown to be highly likely mediated via activity at CB2 receptors[1]. In a separate experiment, a single dose of Olorinab (APD 371) (10 mg/kg, PO) inhibits paw withdrawal threshold for up to 4 hours after administration. |
Synonyms | APD 371 |
Molecular Weight | 357.41 |
Formula | C18H23N5O3 |
CAS No. | 1268881-20-4 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Olorinab 1268881-20-4 G蛋白偶联受体 Cannabinoid Receptor APD 371 Inhibitor inhibitor inhibit